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The  Cancer  Risk  Management  Model  (CRMM)  initiative  of  the Canadian  Partnership  Against  Cancer
offers  policy  makers  a tool  for  making  decisions  regarding  prevention  and screening  for  their  particular
landscape.
The cervical  cancer  component  of  CRMM  is  complex  because  the  development  of cervical  cancer
depends  on  HPV  infection  and  has to take  account  of the  fact that  individuals  must come  in  contact  with
one  another  for HPV  to spread.  Two  tightly  coupled  models  were  built,  one  for  the  infectious  spread  of
HPV  (CRMM-HPV),  and  the other  for the  pathway  from  infection  to disease  onset,  progression,  screening,
treatment,  and  mortality  (CRMM-Cervical).  This  paper  provides  an  overview  of  methods  and  function-
ality  for  CRMM  components  which  simulate  vaccination,  screening,  HPV  incidence,  disease  progression,
and  cancer  incidence.
CRMM-HPV  is a continuous-time,  interacting-agent,  Monte-Carlo  microsimulation  model  that  simu-
lates  sexual  networks  and  HPV  transmission.  Six HPV  groups  (6,  11,  16,  18, other  non-carcinogenic,  other
carcinogenic)  and two  vaccination  types  (bivalent,  quadrivalent)  were  modeled.  Input  parameters  include
demography,  sexual  debut,  partnership  formation/separation  and  virus  transmission,  clearance,  natural
immunity.  CRMM-HPV  provides  a  100-year  projection  of impacts  of vaccinations  on  HPV infections.
Results  were  scaled  to reﬂect  the  Canadian  population  aged  10+  in 2011.
Various  vaccination  scenarios  can  be  compared  by  altering  vaccination  program  design  (target  age,
sex,  program  years,  participation  rate, vaccine  type),  vaccine  efﬁcacy,  duration  of protection  and  previ-
ous  vaccination  status.  These  parameters  enable  users  to  explore  impacts  of various  scenarios  such  as
targeting  various  age  groups,  adding  boys,  and  booster  and  catch-up  programs.
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Introduction
Canada shares with Finland and the United States the distinc-
tion of an 80% reduction in mortality from cancer of the cervix
as a result of the application of cytology screening [1]. However,
in contradistinction to Finland, this has been achieved following
a very substantial investment in resources, largely because of the
generally accepted view that screening should begin soon after the
initiation of sexual activity, and be annual. In contrast, in the orga-
nized program in Finland women age 30–59 are screened every ﬁve
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.
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ears. Detailed analysis of Canadian data has pointed to the rarity
f cervix cancer and the lack of effectiveness of cytology screening
n young women [2,3]. A working group of the International Agency
or Research on Cancer concluded that screening should not begin
ntil age 25 or more [4].
Canada was one of the ﬁrst countries to initiate screening with
ervical cytology. The ﬁrst program began in British Columbia in
949 [5] and programs gradually extended across the country. In
he mid  1970s, it was shown that the extent of the reduction in cer-
ical cancer mortality was dependent on the intensity of screening
6], and a succession of national Task Forces recommended several
easures to increase the effectiveness and efﬁciency of screening
y introducing fully organized programs [7–9]. As the response
f the provinces and territories to these recommendations was
atchy, a pan-Canadian Cervical Screening Network was  initiated in
004 to foster collaboration and support for the recommendations.
The Canadian Partnership Against Cancer initiated its Cancer
isk Management Model (CRMM)  initiative during its ﬁrst 5-year
andate [10]. The initial priorities were the development of a
icrosimulation model to evaluate the future burden of cancer
n Canada, focusing on areas where it was felt progress could be
ade. The ﬁrst two disease-speciﬁc models completed were on
ung and colorectal cancer [11,12]. In view of the major invest-
ent in screening for cancer of the cervix in Canada it was  decided
hat a model for cervical cancer could provide input into the devel-
pment of policies for organized screening and dovetail into the
olicy of promoting vaccination of teenage girls against human
apillomavirus (HPV) types 16, 18, 6 and 11, initiated in Canada in
ome provinces in 2007 (Nova Scotia, Ontario and Prince Edward
sland), others in 2008 (Alberta, British Columbia, Manitoba, New
runswick, Quebec, Saskatchewan) and the North West Territories
nd the Yukon in 2009.
Cancer of the uterine cervix is unique among cancers as it has a
ingle necessary cause, infection with an oncogenic human papil-
omavirus (HPV) [13]. Such infection is not sufﬁcient for cancer to
ccur. Other co-factors including parity, smoking, oral contracep-
ive use, and possibly other infections of the female genital tract,
nteract in various combinations with the necessary cause to induce
he development of cancer. However, the considerable amount of
nformation now available on HPV prevalence, HPV infection by
ge, and the extent to which such infections become persistent
r are cleared by natural immune mechanisms make it possible
o model HPV infection and the incidence of cervical cancer, as
ell as its occurrence via preclinical precursors. It is also possi-
le to estimate the likely cost-effectiveness of different approaches
o vaccination against HPV infection, screening and treatment.
The cervical cancer model in CRMM is more complex than the
ung and colorectal cancer models [11,12] because the develop-
ent of cervical cancer depends on HPV infection and individuals
ust come in contact with one another for the disease to spread.
or cervical cancer two coupled models were built, one for the
nfectious spread of HPV within a population, including the effects
f vaccination (CRMM-HPV) and the other for the pathway from
nfection to disease onset, progression, screening, treatment, and
ortality (CRMM-Cervical). This approach allowed the simulation
f large interacting populations without sacriﬁcing detail and accu-
acy in disease progression, screening, treatment, costs, mortality
rom cervical cancer, and other cause mortality.1CRMM-HPV is an interacting agent model which simulates
he process of HPV transmission through sexual interactions in
 dynamic network of male–female partnerships, accounting for
1 CRMM-HPV and CRMM-Cervical are freely available. Interested users can access
he models through: www.cancerview.ca/cancerriskmanagement after completing
 straightforward sign-up process.cer Policy 4 (2015) 1–6
evolving sex and age-dependent patterns of partnership forma-
tion, dissolution, and duration. Detailed HPV infection rates from
this simulation are then input into CRMM-Cervical to initiate
infections in the isolated simulated individuals in that model.
CRMM-Cervical models subsequent cervical precursor lesion inci-
dence and progression in infected individuals. CRMM-Cervical
is a non-interacting agent model which simulates treatments,
health and economic impacts, and evaluates the impact of differ-
ent approaches to vaccination, screening, and treatment. Processes
which do not involve interaction between individuals are modeled
identically in CRMM-HPV and CRMM-Cervical. These include sex-
ual debut, vaccination, HPV clearance, natural immunity, and
infection persistence.
The present paper describes the assumptions for CRMM-HPV,
their validation and the methodology applied in developing the
resultant model; and the results of incorporating this natural his-
tory model into CRMM-Cervical to simulate the effects of HPV
vaccination.
Materials and methods
The CRMM,  a web-based microsimulation tool, was used to cre-
ate customized Canadian population-based scenarios that model
infection and clearance of HPV and progression/regression through
pre-clinical cervix cancer states and ultimately to invasive cervical
cancer.
Data to populate the model has been obtained from published
and unpublished sources. A working group on cervical cancer (the
present authors) was established, and a series of consultations
were held with national and international experts. The develop-
ment work was largely performed by SG and the Statistics Canada
team.
CRMM-HPV was  developed along similar lines to that of van de
Velde et al. [16]. The features of CRMM-HPV include:
• Non-sexually active individuals enter the simulated population at
10 years of age. The model represents an open stable population
where the rate of entry into the population balances age and sex-
speciﬁc Canadian death rates.
• Both stable and casual sequential monogamous partnerships are
modeled. Girls and boys are assigned a sexual activity level
and become sexually active at a given age by ﬁtting the model
to empirical data on sexual debut. Once sexually active, single
females form new partnerships at a rate based on age and level
of sexual activity. The male partner is chosen from the single male
population based on age, activity level, and onset of male sexual
debut. Stable partnerships dissolve at rates based on female age
and sexual activity level.
• The model represents the transmission and natural history of HPV
types 16 and 18 separately, as well as a composite category con-
sisting of all other high-risk HPV types. Low risk HPV  types 6, 11,
and a composite category of remaining low risk types are also
represented.
• The probability of HPV transmission from an infected individual
to his/her susceptible partner is modeled per sex act. Conse-
quently, the probability of transmission per partnership is age and
level of sexual activity-speciﬁc, as it depends on the frequency of
sex acts per unit time and the duration of the partnership.
• Virus natural history is modeled to incorporate multiple viral
types, per-act transmission and clearance of HPV, natural
acquired immunity and persistent infection.
• The duration and the degree of the vaccine effectiveness can be
speciﬁed by the user, as well as other characteristics of the vacci-
nation program such as targeted ages, sex, and program roll-out.
A.B. Miller et al. / Journal of Cancer Policy 4 (2015) 1–6 3
Fig. 1. Fit of modeled HPV prevalence. Dotted lines indicate upper and lower bounds of ﬁt target. Solid lines refer to model output, each simulated from one of the 16 input
parameter vectors estimated using a Bayesian approach discussed in Method section. Note that all solution points fell within the ﬁt target bounds shown above during the
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parameter estimation process. Some of the simulated solution points in the chart fal
sed  to produce the chart and those used during estimation.
ource: CRMM-HPV version 1.7.1.0.
The model was implemented as follows:
The event-based microsimulation model was written using the
programming language Modgen developed by Statistics Canada.2
A 100-year evolution is included at the start of all simulations to
obtain a stable behavioral network and viral transmission pat-
terns.
This is followed by a 100-year simulation of a vaccination inter-
vention.
The typical simulation size is 250,000 interacting persons. Sixteen
independent simulations, each based on a systematically selected
parameter vector from the posterior distribution, are performed
to assess the statistical reliability of results. Altogether, approxi-
mately 2.1 billion events are simulated in each run.
The behavioral and HPV natural history parameters of CRMM-
PV were estimated using a Bayesian approach with rejection
ampling, as described in van de Velde et al. [16], with some mod-
ﬁcations. The result is a sample of parameter vectors from the
osterior distribution. When the model is run with any member
f that sample, outputs satisfy constraints imposed by empirical
ggregate data (Fig. 1 shows an example of ﬁt result). These con-
training data were obtained from surveys of sexual behavior [17],
creening programs [5,6], clinical trials [14], and from additional
mpirical sources described in [16].
It was initially decided to attempt to ﬁt the model using HPV
revalence rates as documented by Moore et al. [14]. However the
2 http://www.statcan.gc.ca/microsimulation/modgen/modgen-eng.htm.de this target bounds. This is due to Monte Carlo variation between the simulations
estimation procedure for CRMM-HPV was not able to match with
data from the Moore study for younger and older age groups. Subse-
quently, unpublished data were obtained on HPV prevalence from
an ongoing Canadian screening trial evaluating HPV DNA tests vs.
cervical cytology (the HPV FOCAL trial) [15]. The ﬁtting procedure
was able to successfully estimate HPV transmission, clearance and
persistence rates consistent with HPV prevalence by age from the
Focal trial.
The initial ﬁt of modeled HPV prevalence did not ﬁt well with
published data. A number of steps were then taken to modify the
modeled prevalence. These steps included:
– Aligning natural immunity with data published by Van de Velde
et al. [16] to derive estimated probability of life-long immunity
at infection clearance.
– Adding parameters to represent persistent HPV infection result-
ing in estimated probability that a person will be unable to clear
HPV if they are infected.
– Using the HPV-high risk prevalence by age from the Focal trial as
a key empirical constraint.
– Using the HPV target prevalence from Moore et al. [14] rather
than from Van de Velde et al. [16] to estimate HPV-16 prevalence
by age from the HPV Focal trial, and estimate the prevalence of
other HPV strains, consistent with the Focal trial. As a result, a
much closer ﬁt with published data was  achieved (Fig. 1).CRMM-Cervical simulates disease progression and remission
through a sequential series of clinical phases. HPV high-risk
infection is required to progress from one phase to the next.
Phase-to-phase progression and remission rates were estimated by
4 A.B. Miller et al. / Journal of Cancer Policy 4 (2015) 1–6
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ﬁig. 2. Simulated prevalence of those ever infected with an oncogenic HPV type. Sim
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ource: CRMM-HPV version 1.7.1.0.
alibrating the model using empirical data on prevalence by dis-
ase phase, in the context of historical screening and treatment
rograms. Results after calibration are consistent with observed
ncidence rates and staging as recorded in the Canadian Cancer
egistry.
Vaccination program strategies are speciﬁed in detail in CRMM-
PV. The impact of vaccination on HPV incidence is passed from
RMM-HPV to CRMM-Cervical so that full simulations from vac-
ination to HPV incidence to cervical cancer can be conducted
nd evaluated. The two-model approach was adopted to maxi-
ize available computational power under two different modeling
rchitectures: CRMM-HPV simulates infectious disease where the
ontact network and transmission of HPV is a central component,
hich is very computer memory intensive and limits the size of the
nteracting-agent population; CRMM-Cervical models the cancer
here contacts do not play a role, which allows agents to be simu-
ated independently and for very large simulation sizes. Further, the
RMM-Cervical population is representative of the Canadian pop-
lation, whereas the CRMM-HPV population is a demographically
tationary population.
Speciﬁc aspects of potential HPV vaccination programs in the
odel include type of vaccine, e.g. bivalent or quadrivalent, the
ge to vaccinate, whether the program would be restricted to girls
r include boys, whether a catch-up program at later ages would
e used, the coverage of the program, its effectiveness, including
mmunity duration (i.e. lifelong vs. waning) and the effect of revac-
ination at a later age.
Examples of HPV vaccination strategies simulated here to illus-
rate functionality include:
 Target 12 year olds starting in 2007 at a coverage rate of 70% each
year, the ﬁrst vaccinated cohort reaches age 25 in the year 2020.
 The effect of adding vaccination of boys of similar ages.
 Increasing the coverage among girls to 90%.
Simulations were performed using CRMM-HPV version 1.7 and
RMM-Cervical version 2.1.
The HPV target prevalence from Moore et al. [14] rather thanrom Van de Velde et al. [16] was used to estimate HPV-16 preva-
ence by age from the HPV Focal trial, and the prevalence of other
PV strains, consistent with the Focal trial. As a result, a much closer
t with published data was achieved (Fig. 1).n of 250,000 interacting agents. HPV-HR indicates HPV infection with any high-risk
Results
The (simulated) proportion of the female population which has
ever had an HPV-HR infection (i.e. any cancer-causing type) so far in
their lifetimes is depicted in Fig. 2. In the simulation, HPV infection
from high-risk types is highly prevalent in younger women so that
by 30 years-old, 65% of females have been previously infected. The
proportion plateaus at 70% in the simulation.
An example of the modeled impact of the effect of vaccination of
girls at age 12 with 70% coverage and protection continued indef-
initely on the number of females infected with HPV 16 and/or 18
is given in the upper curve in Fig. 3. The initial impact is small,
and not detectable until about 3 years after vaccination, reaches a
maximum at about year 50, and then persists at that level. Simi-
lar time relationships are seen for two other vaccination scenarios.
However, it is apparent that a greater effect was simulated from
vaccinating 90% of the eligible population of girls, than trying to
supplement lack of participation of girls by vaccinating a smaller
proportion of similar aged boys. The impact on cervical cancer inci-
dence for a range of other scenarios, with variation of participation
in vaccination of girls aged 12 are summarized in Table 1. Gener-
ally, the simulation shows that the impact of vaccination on cervical
cancer incidence is modest over the 40-year period following vac-
cination.
Discussion
Important health policy decisions can be greatly aided by infor-
mation on the likely prospective impact of alternative cancer
control interventions. The relevant policy scenarios often involve
situations where conventional empirical calculations are insufﬁ-
cient. Policy scenarios like various HPV vaccination options are
simply too complex, and involve too many different factors. As
a result, simulation modeling is becoming the method of choice.
Simulation models are able to bring together many diverse strands
of empirical evidence in a way  that produces relevant outputs,
where the assumptions are made explicit, and where parame-
ters for which a strong empirical basis is lacking can be varied in
sensitivity analyses. The HPV and cervical components of CRMM
have been developed to facilitate decision making in precisely this
way. This is important in Canada where the provinces, which have
jurisdiction over health care, may  have different cervical cancer
A.B. Miller et al. / Journal of Cancer Policy 4 (2015) 1–6 5
Fig. 3. Inﬂuence of vaccination of girls and boys on rates of females infected by HPV 16/18 (per 1000 female population aged 10 years and older). Simulation of 250,000
interacting agents; Vaccinating girls (and boys) annually with quadrivalent vaccine; Vacc
program years indicate pre-vaccination years.
Source: CRMM-HPV version 1.7.1.0.
Table 1
The effect of varying participation in vaccination and cytology screening on the
incidence of cervical cancer.
Vaccination
participationa
Participation in
cytology
screeningb
Cumulative incidence per
100,000 from 2015 to 2050
None None 15.8
70% None 13.0
None 80% 7.6
70% 80% in
unvaccinated
6.7
50% 80% 6.5
70% 80% 6.2
90% 80% 5.9
Source: CRMM-HPV version 1.7.1.0 and CRMM-Cervical version 2.1.3.0.
a Vaccinations were simulated in CRMM-HPV with the simulation of 250,000
interacting agents. The vaccination programs targeted 12-year old girls annually
with quadrivalent vaccine of various participation rates. Vaccine efﬁcacy was  set to
be  perfect (100% lifetime protection). The vaccination program assumed to begin in
2008.
b Cytology screening and cervical cancer incidence were simulated in CRMM-
Cervical with the simulation of 32 million cases and scaled to the size of the Canadian
population. Cytology screening in all scenarios is given 3-yearly at ages 21–69 start-
ing  from year 2013. Cytology screening prior to 2013 are given every 1–2 years at
a
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CRMM-HPV was  initially developed using information availableges 16–65 at historical levels of participation.
ncidence rates and resource capacity. This may  require the adop-
ion of different policies for the implementation of vaccination and
creening programs.
Vaccination of girls age 10 or more against infection with HPV 16
nd 18 has been increasingly accepted across Canada, with varying
ates of uptake. Although in the present paper we  have modeled
arious scenarios for Canada as a whole, it is anticipated that the
odel will eventually be applied on a provincial basis.
The results presented here are preliminary, and will be
xpanded in a subsequent manuscript using CRMM-Cervical to
nvestigate incidence and mortality endpoints, as well as costs,
ealth beneﬁts and cost-effectiveness of different approaches to
creening (Popadiuk et al., in preparation). However, already it is
pparent that the major beneﬁt from vaccination on incidence of
he disease will not be seen for 40 years.ine efﬁcacy was  set to be perfect (100% lifetime protection); Negative vaccination
High compliance with screening is essential to obtain an impor-
tant impact upon incidence of the disease. In this application of
CRMMCervical, we  have assumed an 80% participation rate in cervi-
cal screening in the last 3 years is achieved, as is the case in Canada
currently [18]; such high compliance is sought to ensure that as
many as possible of the high-risk group are screened.
One current limitation to the model is that we do not have esti-
mates for health-related quality of life (HRQL) indicators associated
with pre-cancerous lesions or any potential impact to HRQL result-
ing from cervical cancer screening and treatment. Also, to date we
have not incorporated the effect of vaccination on other HPV related
cancers. But these can be incorporated in future iterations of the
model as can the impact of new, e.g. nonavalent vaccines.
In conclusion, CRMM is a powerful, accessible and user-friendly
tool. A wide variety of vaccination policy scenario projections can
be compared by altering only a few parameters. The platform allows
researchers and policy makers to run a complex model in a simple
and ﬂexible manner via the internet, to support policy-makers in a
readily understandable manner.
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